Valuation

ALXOALX Oncology Holdings Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

−15.4% today · −8.7% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 2% of the instruments we score

Quality, Trend, Stability: among the weakest; priced higher than most peers. No dividend.

ALX Oncology Holdings Inc (ALXO) valuation against sector peers: P/B 1.2, free-cash-flow yield −44.6%, P/S 39.1.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricALXOSector medianvs median
P/E—29.1 · n=156—
P/B1.23.8 · n=30669% below
P/S39.14.1 · n=299857% above
EV/EBIT—25.9 · n=143—
Free-cash-flow yield−44.6%1.5% · n=2883,029% below
Dividend yield0.00%0.00% · n=361—
Return on equity−80.6%−2.7% · n=305—
Return on invested capital−92.0%0.4% · n=27821,959% below
Gross margin—63.1% · n=204—
Net debt / EBITDA—1.24 · n=148—

Value factor: 8 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co46.631.9—1.5%0.6%6/10
JNJJohnson & Johnson40.78.0—3.1%1.9%8/10
ABBVAbbVie49.5—27.33.7%3.0%6/10
MRKMerck147.78.1—4.1%2.3%8/10
UNHUnitedHealth22.33.417.06.4%2.3%10/10
TMOThermo Fisher Scientific35.54.633.83.0%0.3%9/10
AMGNAmgen26.517.323.03.8%2.2%8/10
GILDGilead Sciences—15.9—6.6%1.9%4/10
ABTAbbott41.93.933.73.4%2.7%6/10
PFEPfizer42.21.9—6.9%7.2%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 06 Aug 2026